Amgen’s Repatha reduces CV events risk in FOURIER trial

Amgen’s Repatha led to higher risk reduction in patients who have had a recent heart attack. Credit: StockSnap from Pixabay.



  • Amgen’s Repatha reduces CV events risk in FOURIER trial